Role of autologous platelet-rich plasma in treatment of long-bone nonunions: a prospective study
- 461 Downloads
Fracture union is a complex biological process, which depends upon several systemic and local factors. Disturbance of any of these factors may lead to nonunion of the fracture. These nonunions have a huge impact on quality of life as well as socioeconomical aspects. The platelets on activation release a number of growth factors and differentiation factors, which play important role in fracture healing. This study aimed to look for efficacy of platelet-rich plasma in the treatment of established fracture nonunions of long bones.
A total of 94 patients with established nonunion of long bone (35 tibia, 30 femur, 11 humerus, 4 radius, 12 ulna, 2 with both radius and ulna) were included in this study. We injected 15–20 ml of autologous platelet-rich plasma (>2,000,000 platelets/μl) under image intensifier at each nonunion site. The fracture union was evaluated clinically and radiologically regularly at monthly interval till 4 months.
Eighty-two patients had their fracture united at the end of 4 months. Thirty-four patients showed bridging trabeculae on X-rays at the end of 2 months, while 41 patients showed bridging trabeculae at the end of third month. Twelve patients did not show any attempt of union at 4 months and were labeled as failure of treatment. There were no complications.
Platelet-rich plasma is a safe and effective treatment for the treatment of nonunions. More studies are needed to look into molecular mechanism of this fracture healing acceleration by platelet-rich plasma.
KeywordsNonunion Platelet-rich plasma (PRP) Femur Tibia Humerus Radius
We would like to thank Indian Council of Medical Research (ICMR) for funding this study.
Compliance with ethical standards
Conflict of interest
- 10.Bucholz RW, Einhorn TA, Marsh JL (2006) Bone and joint healing. In: Bucholz RW, Heck-man JD, Court-Brown C (eds) Rockwood & Green’s fractures in adults, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 300–311Google Scholar
- 26.Bielecki TM, Gazdzik TS (2006) Percutaneous injection of autogenous growth factors in patient with nonunion of the humerus. A case report. J Orthop 3(3):15Google Scholar
- 31.Dallari D, Fini M, Stagni C, Torricelli P, Nicoli Aldini N, Giavaresi G et al (2006) In vivo study on the healing of bone defects treated with bone marrow stromal cells, platelet-rich plasma, and freeze-dried bone allografts, alone and in combination. J Orthop Res 24(5):877–888CrossRefPubMedGoogle Scholar
- 38.Parsons P, Butcher A, Hesselden K, Ellis K, Maughan J, Milner R et al (2008) Platelet-rich concentrate supports human mesenchymal stem cell proliferation, bone morphogenetic protein-2 messenger RNA expression, alkaline phosphatase activity, and bone formation in vitro: a mode of action to enhance bone repair. J Orthop Trauma 22(9):595–604CrossRefPubMedGoogle Scholar
- 41.Ogino Y, Ayukawa Y, Kukita T, Koyano K (2006) The contribution of platelet-derived growth factor, transforming growth factor-beta1, and insulin-like growth factor-I in platelet-rich plasma to the proliferation of osteoblast-like cells. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101(6):724–729CrossRefPubMedGoogle Scholar
- 42.Bielecki T, Gazdzik TS, Szczepanski T (2006) Re: “The effects of local platelet rich plasma delivery on diabetic fracture healing”. What do we use: platelet-rich plasma or platelet-rich gel? Bone 39(6):1388; author reply 1389 Google Scholar
- 46.Turajane T, Thitiset T, Honsawek S, Chaveewanakorn U, Aojanepong J, Papadopoulos KI (2014) Assessment of chondrogenic differentiation potential of autologous activated peripheral blood stem cells on human early osteoarthritic cancellous tibial bone scaffold. Musculoskelet Surg 98(1):35–43CrossRefPubMedGoogle Scholar
- 47.Gonshor A (2002) Technique for producing platelet-rich plasma and platelet concentrate: background and process. Int J Periodontics Restor Dent 22(6):547–557Google Scholar